Patients with type III ESCC (ie, Siglec-15 negativity and PD-L1 positivity) had the worst outcomes and were most likely to benefit from a single anti–PD-1/PD-L1 blocker. Here, PDCD1 is linked to esophageal squamous cell carcinoma.